Montai Health
Dan Adams has a diverse work experience in the field of biology and research. Dan is currently the Director - Head of In Vitro Biology & Platform at Montai Health, where they started in April 2023. Prior to this role, they worked at Skyhawk Therapeutics from January 2020 to April 2023, first as a Principal Scientist & Group Leader and then as a Senior Principal Scientist & Group Leader. From 2017 to 2019, they were a Scientist at Amgen. Before that, they joined Heprotech as a Scientist in October 2014 and played a key role in the company's scientific research and development efforts. Dan also worked as a Postdoctoral Research Associate at Boston College in 2014 and as a Graduate Research Assistant at the University of Colorado at Boulder from 2010 to 2013. Their earliest role was as a Research Assistant at the University of Colorado Boulder from 2008 to 2010, where they focused on the dynamics of splicing snRNP assembly and catalysis using C. elegans as a model. Through their various roles, Dan has gained extensive experience in target validation, assay development, screening, hit-to-lead optimization, preclinical studies, and research in the field of biology and neuroscience.
Dan Adams attended Clark University from 2003 to 2007, where they obtained a Bachelor of Arts (B.A.) in Biochemistry and Molecular Biology. Dan then pursued a Doctor of Philosophy (Ph.D.) degree at the University of Colorado Boulder from 2007 to 2013, specializing in Cell/Cellular and Molecular Biology.
This person is not in any teams
This person is not in any offices
Montai Health
Montai is harnessing nature's power through digital technology to treat and prevent chronic disease, hence improving health outcomes for as many people as possible. To address this crucial global concern, the business is pioneering cutting-edge technology to develop AnthromoleculeTM medications, which are derived from a privileged class ofcompounds with a history of safe human use. Our human-centered foundation can enable the rapid and repeatable development of safe, efficacious, and accessible medicines for as many diseases and people as possible by creating the world's first Anthromolecule Bioactivity Atlas, which comprehensively maps potent connections to all known biological pathways underlying disease.